Chronic kidney disease: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• SGLT2 24
• GLP-1 8
• NLRP3 0
• NRF2 1
• PI3K 0
• APOL1 3
• STAT3 1
• AKT 0
• mTOR 1
• PPAR 0
• AMPK 0
• SIRT1 0
• HIF-1 0
• TLR4 0
• MAPK 0
• STING 0
• CTNNB1 0
• TP53 0
• ERK 0
• GPX4 0
• IL-6 3
• VEGF 0
• JAK 0
• IL-1 1
• JNK 0
• TNF 1
• DPP-4 0
• EGFR 0
• YAP 0
• FGFR 0
• PCSK9 0
• APOE 0
• PINK1 0
• TFEB 0
• BCMA 3
• HMGB1 0
• HSP90 0
• BDNF 0
• GIP 0
• CD40 0
• CD47 0
• COX-2 0
• IL-17 1
• PKM2 0
• PSMA 0
• ABL1 0
• CCR5 0
• EZH2 0
• METTL3 0
• MMP-9 0
• PKD1 0
• PTEN 0
• SNCA 0
• ANGPTL3 0
• BCL-2 0
• CD19 1
• CD38 0
• CDK4/6 0
• CXCR4 0
• FTO 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NEI · R01

  Mobile Strategy for Improving Eye Health of Kidney Patients Treated with Dialysis (SIGHT)

  University of Washington· Seattle, United States· US$1,383,760 awarded in fiscal year 2026· until Aug 2031

• NIH NIDDK · K08

  Natural killer T cells in acute cardiorenal syndrome

  Oregon Health & Science University· Portland, United States· US$160,584 awarded in fiscal year 2026· until Jul 2031

• NIH NIDDK · R01

  The Interaction between Food Craving and Food Choice in Humans: A Computational Intracranial Electrophysiological Study

  Icahn School of Medicine at Mount Sinai· New York, United States· US$854,983 awarded in fiscal year 2026· until Aug 2031

• NIH NIDDK · R01

  mRNA Splicing in Podocyte Biology and Glomerular Disease

  State University New York Stony Brook· Stony Brook, United States· US$755,725 awarded in fiscal year 2026· until Jun 2030

• NIH NIDDK · U01

  Mitigating Diabetic Ketoacidosis in People with T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor: Ketosis Risk Factor Determination and Incorporation into an Enhanced Glucose Ketone Report

  Healthpartners Institute· Bloomington, United States· US$1,542,828 awarded in fiscal year 2026· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-ERC

  Deciphering the gene regulation of oxygen homeostasis and human fitness (ErythrO2Reg)

  Karolinska Institutet· Stockholm, Sweden· EU contribution €1,500,000· until Mar 2032

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-generation therapeutics for vascular diseases (TIE2gether)

  Helsingin Yliopisto· Helsinki, Finland· EU contribution €4,273,568· until Jan 2031· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Formaldehyde crosslink exposure and genomic ageing (FORCE)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €2,693,628· until Dec 2031

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Early Inflammation in Fibrotic Niches of Chonic Kidney Disease (InFibrosis)

  Universite Paris Cite· Paris, France· EU contribution €1,498,100· until Dec 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Direct implication of the Calcium Sensing Receptor in Vascular Calcifiction and Atherosclerosis in Chronic Kidney Disease (AtheroCaSR)

  Cardiff University· Cardiff, United Kingdom· EU contribution €325,435· until Feb 2029

10 of 1,522 running projects, newest first. Listed amounts together: US$832.0m + €145.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 29
• Organoids 10
• Mendelian Randomization Analysis 78
• CRISPR-Cas Systems 5
• Gene Expression Profiling 88
• Sequence Analysis, RNA 4
• Whole Genome Sequencing 2
• Exome Sequencing 19
• Proteomics 103
• Metabolomics 91
• Mass Spectrometry 18
• Flow Cytometry 10
• Immunohistochemistry 19
• Liquid Biopsy 2
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 70
• Machine Learning 176
• Deep Learning 23
• Cohort Studies 556
• Genome-Wide Association Study 79

• Genome-Wide Association Study of Kidney Function Decline in ~100 000 Taiwanese Adults-A Taiwan Biobank Cohort.

  Nephrology (Carlton), Nov 2026

• KDM1A regulates nephron progenitor programs and is associated with human kidney disease risk.

  Nephrol Dial Transplant, Oct 2026

• Unraveling the shared genetic architecture of metabolic bone diseases via genomic structural equation modeling and multi-omics integration.

  PLoS One, Oct 2026

• From Susceptibility Loci to Therapeutic Targets: The Genetic Architecture of IgA Nephropathy.

  Int J Mol Sci, Oct 2026

• FGF-23 is associated with increased risk of abdominal aortic calcification: A Mendelian randomization study with phosphate as a potential mediator.

  Medicine (Baltimore), Oct 2026

• Protein mediators of chronic kidney disease in Type 2 diabetes: A mendelian randomization study.

  PLoS Med, Sept 2026

• Genome-wide association study of sarcopenia index reveals sex-stratified genetic architecture.

  Biol Sex Differ, Aug 2026

• A multi-omics Mendelian randomization framework identifies PM2.5-annotated candidate regulatory genes and methylation-linked pathways in diabetic nephropathy.

  Clin Epigenetics, Aug 2026

• Genome-wide DNA methylation analysis revealed epigenetic mechanism underlying end-stage renal disease.

  Nat Commun, Aug 2026

• The Impact of Omega Fatty Acids on DKD: A Multimodal Study Integrating Mendelian Randomization, Proteomic Mediation Analysis, and Meta-Analysis.

  FASEB J, Jul 2026

See which targets of this disease your abstract mentions, and go to the people working on them.